Aptevo Therapeutics Inc (APVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aptevo Therapeutics Inc (APVO) has a cash flow conversion efficiency ratio of -0.686x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.96 Million) by net assets ($11.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See APVO days of operational coverage to measure how many days the company can operate on defensive assets alone.
Aptevo Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Aptevo Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aptevo Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptevo Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ABAS Protect AB
ST:ABAS
|
N/A |
|
Terra Uranium Ltd
AU:T92
|
-0.053x |
|
RH Bophelo Ltd
JSE:RHB
|
-0.003x |
|
AIxCrypto Holdings, Inc.
NASDAQ:AIXC
|
-0.056x |
|
NV Gold Corp
V:NVX
|
-0.027x |
|
Meihua International Medical Technologies Co. Ltd.
NASDAQ:MHUAF
|
0.055x |
|
Samfine Creation Holdings Group Limited
NASDAQ:SFHG
|
0.035x |
|
Volato Group Inc.
NYSE MKT:SOAR
|
-3.163x |
Annual Cash Flow Conversion Efficiency for Aptevo Therapeutics Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Aptevo Therapeutics Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Aptevo Therapeutics Inc (APVO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.38 Million | $-25.59 Million | -1.472x | +70.56% |
| 2024-12-31 | $4.75 Million | $-23.79 Million | -5.002x | -421.15% |
| 2023-12-31 | $12.22 Million | $-11.73 Million | -0.960x | +17.93% |
| 2022-12-31 | $17.97 Million | $-21.02 Million | -1.170x | +93.44% |
| 2021-12-31 | $1.22 Million | $-21.68 Million | -17.828x | -909.07% |
| 2020-12-31 | $16.59 Million | $-29.32 Million | -1.767x | +50.64% |
| 2019-12-31 | $11.84 Million | $-42.38 Million | -3.579x | -111.63% |
| 2018-12-31 | $30.41 Million | $-51.42 Million | -1.691x | -233.72% |
| 2017-12-31 | $82.03 Million | $-41.57 Million | -0.507x | +30.48% |
| 2016-12-31 | $50.57 Million | $-36.86 Million | -0.729x | -32.49% |
| 2015-12-31 | $88.62 Million | $-48.76 Million | -0.550x | -10.74% |
| 2014-12-31 | $94.61 Million | $-47.01 Million | -0.497x | -- |
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune … Read more